scholarly journals Broad HIV neutralization by a vaccine-induced cow antibody

2020 ◽  
Vol 76 (a1) ◽  
pp. a113-a113
Author(s):  
Robyn Stanfield
Keyword(s):  
2008 ◽  
Vol 2 (1) ◽  
pp. 47-58 ◽  
Author(s):  
Anna Laurén ◽  
Eva Maria Fenyö
Keyword(s):  

2011 ◽  
Vol 108 (34) ◽  
pp. 14079-14084 ◽  
Author(s):  
J. R. Keeffe ◽  
P. N. P. Gnanapragasam ◽  
S. K. Gillespie ◽  
J. Yong ◽  
P. J. Bjorkman ◽  
...  
Keyword(s):  

2011 ◽  
Vol 208 (3) ◽  
pp. 439-454 ◽  
Author(s):  
Claudia R. Ruprecht ◽  
Anders Krarup ◽  
Lucy Reynell ◽  
Axel M. Mann ◽  
Oliver F. Brandenberg ◽  
...  

Interference with virus entry is known to be the principle mechanism of HIV neutralization by antibodies, including 2F5 and 4E10, which bind to the membrane-proximal external region (MPER) of the gp41 envelope protein. However, to date, the precise molecular events underlying neutralization by MPER-specific antibodies remain incompletely understood. In this study, we investigated the capacity of these antibodies to irrevocably sterilize HIV virions. Long-term effects of antibodies on virions can differ, rendering neutralization either reversible or irreversible. MPER-specific antibodies irreversibly neutralize virions, and this capacity is associated with induction of gp120 shedding. Both processes have similar thermodynamic properties and slow kinetics requiring several hours. Antibodies directed to the CD4 binding site, V3 loop, and the MPER can induce gp120 shedding, and shedding activity is detected with high frequency in plasma from patients infected with divergent genetic HIV-1 subtypes. Importantly, as we show in this study, induction of gp120 shedding is closely associated with MPER antibody inhibition, constituting either a primary event leading to virion neutralization or representing an immediate consequence thereof, and thus needs to be factored into the mechanistic processes underlying their activity.


2006 ◽  
Vol 70 (2) ◽  
pp. 21-27
Author(s):  
J PAN ◽  
J CHEN ◽  
H LEE ◽  
G SAHU ◽  
J POAST ◽  
...  
Keyword(s):  

2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Enas Sheik-Khalil ◽  
Mark-Anthony Bray ◽  
Gülsen Özkaya Şahin ◽  
Gabriella Scarlatti ◽  
Marianne Jansson ◽  
...  

2000 ◽  
Vol 2 (2) ◽  
pp. 213-221 ◽  
Author(s):  
Jack H Nunberg ◽  
Kathryn E Follis ◽  
Meg Trahey ◽  
Rachel A LaCasse
Keyword(s):  

2021 ◽  
Author(s):  
Jinchen Wei ◽  
Yanqun Zhang ◽  
Yonglian Zeng ◽  
Yang Yang ◽  
Ronggan Liang ◽  
...  

ABSTRACTAIDS caused by HIV is one of the most serious public health challenges in the world. As we all know, Antiretroviral therapy (ART) is the most effective way to treat AIDS so far, however, forthe reasons of drug resistance, side effects, compliance, economy, limited its using widely. On the other hand, AIDS cannot be completely cured by ART. While the characterization of bnAbs (broadly neutralizing antibodies) in potent HIV neutralization provides considerable insight into HIV curing, it also can be used for passive immunotherapy or combination with ART for HIV-1 treatment. Here we report a novel technology to produce an neutralized activity bnAbs named HIV-1-IgY, which was extracted from the immunized Chicken egg by pNL4-3 virus antigens, and further purified using Water dilution and Salting out method. The specificity, titer and neutralizing activity of HIV-1-IgY was analyzed by Western blotting, ELISA and TZM-bl cell line evaluation system respectively. The results showed that theHIV-1-IgY has high neutralized activity to HIV in vitro; nearly 90% of HIV-1 were neutralized at 1.89μM in TZM-blsystem, which indicated that IgY may be a source of antibodies for AIDS prevention and treatment. Despite its needs to further consider and evaluate neutralized activity in-vivo and the potential mechanisms, Our data showed that we obtained an HIV-1-IgY which could effectively neutralize HIV-l IIIB virus in vitro.


Sign in / Sign up

Export Citation Format

Share Document